L’allo-immunisation érythrocytaire fœtomaternelle dans le système ABO reste la principale cause des maladies hémolytiques du fœtus et du nouveau-né. Objectif: Énoncer une directive sur le recours au traitement prophylactique anti-D dans le but d’optimiser la prévention d el’allo-immunisation fœto-maternelle. Prévention de l’allo-immunisation fœto-maternelle Rh: en sommes-nous là? Division de la médecine fœto-maternelle, et présidente associée, Éducation).

Author: Guzshura Mikazahn
Country: Finland
Language: English (Spanish)
Genre: Literature
Published (Last): 8 June 2011
Pages: 87
PDF File Size: 16.75 Mb
ePub File Size: 20.61 Mb
ISBN: 982-9-34626-910-3
Downloads: 62272
Price: Free* [*Free Regsitration Required]
Uploader: Kajit

Intensity is generally lower than in RhD allo-immunization. We report on three cases showing that ABO allo-immunization can lead to severe hemolytic disease of the newborn with potentially threatening hyperbilirubinemia and complications. Early diagnosis and adequate care are necessary to prevent complications in ABO incompatibility.

A direct antiglobulin test is the cornerstone of diagnosis and should be performed at birth immunisatiin cord blood sampling in all immunisatuon infants born to O mothers, especially if of African origin. Risk factor analysis and attentive clinical monitoring during the first days of life are essential.

No 133-Prévention de l’allo-immunisation fœto-maternelle Rh.

Vigilance is even more important for infants discharged before the age of 72 h. Every newborn should be assessed for the risk of developing severe hyperbilirubinemia and should be examined by a qualified healthcare ummunisation in the first days of life.


Treatment depends on the total serum bilirubin level, which may increase very rapidly in the first 48 h of life in cases of hemolytic disease of the newborn. Phototherapy and, in severe cases, exchange transfusion are immunisatkon to prevent hyperbilirubinemia encephalopathy. Intravenous immunoglobulins are used to reduce exchange transfusion.

Treatments of severe hemolytic disease of matetnelle newborn should be provided and performed by trained personnel in neonatal intensive care units. Journal page Archives Contents list.

Access to the text HTML. Access to the PDF text.

Access to the full text of this article requires a subscription. If you are a subscriber, please sign in ‘My Account’ at the top right of the screen.

Allo-immunisation fœto-maternelle anti-CD10

If you want to subscribe to this journal, see our rates You can purchase this item in Pay Per View: Neonatal ABO incompatibility underlies a potentially severe hemolytic disease of the newborn and requires immunisatioj care.

Minon bJ. Outline Masquer le plan. Top of the page – Article Outline. Contact Help Who are we?


No Prévention de l’allo-immunisation fœto-maternelle Rh.

As foetl the Law relating to information storage and personal integrity, you have the right to oppose art 26 of that lawaccess art 34 of that law and rectify art 36 of that law your personal data.

You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted. Personal information regarding our website’s visitors, including their identity, immunisationn confidential.

The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.

You can move this window by clicking on the headline.